Blood pressure and renal hemodynamic effects of angiotensin fragments

Hypertension Research

Volumn 34, Issue 6, 2011, Pages 674-683

  Yang, Rui ^a   Smolders, Ilse ^a   Dupont, Alain G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

angiotensin fragments; blood pressure; kidney; renal hemodynamics

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN A; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN[1-7]; UNCLASSIFIED DRUG;

ARTERIAL PRESSURE; BLOOD PRESSURE; DIURESIS; HUMAN; KIDNEY BLOOD FLOW; NONHUMAN; PRESSOR RESPONSE; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM BALANCE; SODIUM EXCRETION; VASOCONSTRICTION;

ANGIOTENSIN II; ANGIOTENSIN III; ANGIOTENSINS; ANIMALS; BLOOD PRESSURE; HEMODYNAMICS; HUMANS; KIDNEY; PEPTIDE FRAGMENTS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENAL CIRCULATION; SODIUM;

EID: 79958113688     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.24     Document Type: Review

References (159)

1. Skeggs LT, Lentz KE, Gould AB, Hochstrasser H, Kahn JR. Biochemistry and kinetics of the renin-angiotensin system. Fed Proc 1967; 26: 42-47.
2. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin-angiotensin systems. Regul Pept 1993; 43: 1-20.
3. Dorer FE, Kahn JR, Lentz KE, Levine M, Skeggs LT. Purification and properties of angiotensin-converting enzyme from hog lung. Circ Res 1972; 31: 356-366.
4. Ardaillou R, Chansel D, Chatziantoniou C, Dussaule JC. Biology and functions of renal receptors for angiotensin II and its active fragments. Adv Nephrol Necker Hosp 1998; 28: 225-257.
5. Chansel D, Ardaillou R. Active metabolites derived from angiotensin II. Nephrologie 1998; 19: 427-432.
6. Mustafa T, Lee JH, Chai SY, Albiston AL, McDowall SG, Mendelsohn FA. Bioactive angiotensin peptides: focus on angiotensin IV. J Renin-Angiotensin- Aldosterone Syst 2001; 2: 205-210. (Pubitemid 33685893)
7. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30: 535-541. (Pubitemid 27444228)
8. Jankowski V, Vanholder R, van Der GM, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 2007; 27: 297-302. (Pubitemid 46143043)
9. Paul M, Poyan MA, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803. (Pubitemid 44033382)
10. van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser AH. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001; 60: 2311-2317. (Pubitemid 33070473)
11. Danser AH, Admiraal PJ, Derkx FH, Schalekamp MA. Angiotensin I-to-II conversion in the human renal vascular bed. J Hypertens 1998; 16: 2051-2056. (Pubitemid 29002387)
12. Seikaly MG, Arant Jr BS, Seney Jr FD. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990; 86: 1352-1357. (Pubitemid 20370446)
13. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-251. (Pubitemid 23191415)
14. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
15. Steckelings UM, Kaschina E, Unger T. The AT2 receptor-a matter of love and hate. Peptides 2005; 26: 1401-1409. (Pubitemid 41021474)
16. Harding JW, Wright JW, Swanson GN, Hanesworth JM, Krebs LT. AT4 receptors: specificity and distribution. Kidney Int 1994; 46: 1510-1512.
17. Handa RK, Krebs LT, Harding JW, Handa SE. Angiotensin IV AT4-receptor system in the rat kidney. Am J Physiol 1998; 274: F290-F299.
18. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36: 449-467.
19. Miserey S, Clauser E. Angiotensin II receptors: classification, structure, and signal transduction. Therapie 1998; 53: 205-211. (Pubitemid 28337003)
20. Llorens-Cortes C, Greenberg B, Huang H, Corvol P. Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptasepolymerase chain reaction analysis. Hypertension 1994; 2: 538-548. (Pubitemid 24337822)
21. Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol 1994; 267: E260-E267.
22. Miyata N, Park F, Li XF, Cowley Jr AW. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol 1999; 277: F437-F446. (Pubitemid 29459656)
23. Grone HJ, Simon M, Fuchs E. Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult human kidney. Am J Physiol 1992; 262: F326-F331.
24. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261: R209-R216.
25. Viswanathan M, Tsutsumi K, Correa FM, Saavedra JM. Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem Biophys Res Commun 1991; 179: 1361-1367.
26. Goto M, Mukoyama M, Suga S, Matsumoto T, Nakagawa M, Ishibashi R, Kasahara M, Sugawara A, Tanaka I, Nakao K. Growth-dependent induction of angiotensin II type 2 receptor in rat mesangial cells. Hypertension 1997; 30: 358-362. (Pubitemid 27446093)
27. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997; 30: 1238-1246. (Pubitemid 27476185)
28. Zhuo J, Dean R, MacGregor D, Alcorn D, Mendelsohn FA. Presence of angiotensin II AT2 receptor binding sites in the adventitia of human kidney vasculature. Clin Exp Pharmacol Physiol Suppl 1996; 3: S147-S154. (Pubitemid 26421908)
29. Ruiz-OrtegaM, Esteban V, Suzuki Y, Ruperez M, Mezzano S, Ardiles L, Justo P, Ortiz A, Egido J. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl 2003; 86: S21-S26. (Pubitemid 37159623)
30. Hakam AC, Hussain T. Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. Hypertension 2005; 45: 270-275. (Pubitemid 40179971)
31. Otsuka S, Sugano M, Makino N, Sawada S, Hata T, Niho Y. Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats. Hypertension 1998; 32: 467-472. (Pubitemid 28429135)
32. Zhu YZ, Chimon GN, Zhu YC, Lu Q, Li B, Hu HZ, Yap EH, Lee HS, Wong PT. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport 2000; 11: 1191-1194. (Pubitemid 30262955)
33. Steckelings UM, Wollschlager T, Peters J, Henz BM, Hermes B, Artuc M. Human skin: source of and target organ for angiotensin II. Exp Dermatol 2004; 13: 148-154. (Pubitemid 38380278)
34. Steckelings UM, Henz BM, Wiehstutz S, Unger T, Artuc M. Differential expression angiotensin receptors in human cutaneous wound healing. Br J Dermatol 2005; 153: 887-893. (Pubitemid 41540751)
35. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004; 109: 2296-2301. (Pubitemid 38656868)
36. Matsubara H, Sugaya T, Murasawa S, Nozawa Y, Mori Y, Masaki H, Maruyama K, Tsutumi Y, Shibasaki Y, Moriguchi Y, Tanaka Y, Isawaka T, Inada M. Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron 1998; 80: 25-34. (Pubitemid 28434688)
37. Ingert C, Grima M, Coquard C, Barthelmebs M, Imbs JL. Contribution of angiotensin II internalization to intrarenal angiotensin II levels in rats. Am J Physiol Renal Physiol 2002; 283: F1003-F1010. (Pubitemid 35192467)
38. Guyton AC (ed). Human Physiology and Mechanisms of Disease, 5th edn. WB Saunders: Philadelphia, PA, 1992, 157pp.
39. Lumbers ER. Angiotensin and aldosterone. Regul pept 1999; 80: 91-100. (Pubitemid 29219500)
40. Hall JE. Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol 1986; 250(6, Part 2): R960-R972.
41. Daniels D, Yee DK, Fluharty SJ. Angiotensin II receptor signaling. Exp Physiol 2007; 92: 523-527.
42. Badzynska B, Grzelec-Mojzesowicz M, Dobrowolski L, Sadowski J. Differential effect of angiotensin II on blood circulation in the renal medulla and cortex of anaesthetised rats. J Physiol 2002; 538: 159-166. (Pubitemid 35190045)
43. Champion HC, Czapla MA, Kadowitz PJ. Responses to angiotensin peptides are mediated by AT1 receptors in the rat. Am J Physiol 1998; 274: E115-E123.
44. Li XC, Campbell DJ, Ohishi M, Yuan S, Zhuo JL. AT1 receptor-activated signaling mediates angiotensin IV-induced renal cortical vasoconstriction in rats. Am J Physiol Renal Physiol 2006; 290: F1024-F1033. (Pubitemid 43724901)
45. Rudenstam J, Creutz J, Gothberg G, Karlstrom G, Bergstrom G. Regional renal haemodynamics of angiotensin II infusion under prostaglandin, kinin or converting enzyme inhibition in the Wistar rat. Blood Press 2000; 9: 169-175. (Pubitemid 30341436)
46. Gembardt F, Heringer-Walther S, van Esch JH, Sterner-Kock A, van VR, Le TH, Garrelds IM, Coffman TM, Danser AH, Schultheiss HP, Walther T. Cardiovascular phenotype of mice lacking all three subtypes of angiotensin II receptors. FASEB J 2008; 22: 3068-3077.
47. Yang R, Walther T, Gembardt F, Smolders I, Vanderheyden P, Albiston AL, Chai SY, Dupont AG. Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT1a-receptor mediated. J Hypertens 2010; 28: 487-494.
48. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 1995; 92: 3521-3525.
49. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A. Angiotensin II type 1a receptordeficient mice with hypotension and hyperreninemia. J Biol Chem 1995; 270: 18719-18722.
50. Chen X, Li W, Yoshida H, Tsuchida S, Nishimura H, Takemoto F, Okubo S, Fogo A, Matsusaka T, Ichikawa I. Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J Physiol 1997; 272: F299-F304.
51. Oliverio MI, Best CF, Kim HS, Arendshorst WJ, Smithies O, Coffman TM. Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. Am J Physiol 1997; 272: F515-F520.
52. Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishimura H, Fogo A, Utsunomiya H, Inagami T, Ichikawa I. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 1998; 101: 755-760. (Pubitemid 28096071)
53. Shanmugam S, Sandberg K. Ontogeny of angiotensin II receptors. Cell Biol Int 1996; 20: 169-176. (Pubitemid 26197508)
54. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006; 103: 17985-17990. (Pubitemid 44852272)
55. Plovsing RR, Wamberg CH, Sandgaard NCF, Simonsen JA, Holstein-Rathlou N-H, Høilund-Carlsen PF, Bie P. Effects of truncated angiotensins in humans after double blockade of the renin system. Am J Physiol Regul Integr Comp Physiol 2003; 285: R981-R991. (Pubitemid 37296348)
56. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010; 7: 431-441.
57. Huang WC. Renal hemodynamic and tubular effects of angiotensins II and III. Chin J Physiol 1991; 34: 121-138.
58. Vyas SJ, Jackson EK. Angiotensin II: enhanced renal responsiveness in young genetically hypertensive rats. J Pharmacol Exp Ther 1995; 273: 768-777.
59. Handa RK. Biphasic actions of angiotensin IV on renal blood flow in the rat. Regul Pept 2006; 136: 23-29.
60. Coleman JKM, Krebs LT, Hamilton TA, Ong B, Lawrence KA, Sardinia MF, Harding JW, Wright JW. Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats. Peptides 1998; 19: 269-277. (Pubitemid 28097926)
61. Clayton JS, Clark KL, Johns EJ, Drew GM. Effects of prostaglandins and nitric oxide on the renal effects of angiotensin II in the anaesthetized rat. Br J Pharmacol 1998; 124: 1467-1474. (Pubitemid 28360571)
62. Yang R, Smolders I, De BD, Fouyn R, Halberg M, Demaegdt H, Vanderheyden P, Dupont AG. Brain and peripheral angiotensin II type 1 receptors mediate renal vasoconstrictor and blood pressure responses to angiotensin IV in the rat. J Hypertens 2008; 26: 998-1007. (Pubitemid 351520988)
63. Arendshorst WJ, Brannstrom K, Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 1999; 10: S149-S161. (Pubitemid 29038180)
64. Yamamoto T, Hayashi K, Matsuda H, Kubota E, Tanaka H, Ogasawara Y, Nakamoto H, Suzuki H, Saruta T, Kajiya F. In vivo visualization of angiotensin II-and tubuloglomerular feedback-mediated renal vasoconstriction. Kidney Int 2001; 60: 364-369. (Pubitemid 32587576)
65. Olsen ME, Hall JE, Montani JP, Guyton AC, Langford HG, Cornell JE. Mechanisms of angiotensin II natriuresis and antinatriuresis. Am J Physiol 1985; 249: F299-F307. (Pubitemid 16245322)
66. Bie P, Wamberg S, Kjolby M. Volume natriuresis vs. pressure natriuresis. Acta Physiol Scand 2004; 181: 495-503. (Pubitemid 39078847)
67. Granger JP, Alexander BT, Llinas M. Mechanisms of pressure natriuresis. Curr Hypertens Rep 2002; 4: 152-159.
68. Navar LG, Paul RV, Carmines PK, Chou CL, Marsh DJ. Intrarenal mechanisms mediating pressure natriuresis: role of angiotensin and prostaglandins. Fed Proc 1986; 45: 2885-2891. (Pubitemid 17233722)
69. Zhao D, Navar LG. Acute angiotensin II infusions elicit pressure natriuresis in mice and reduce distal fractional sodium reabsorption. Hypertension 2008; 52: 137-142.
70. Harris PJ. Stimulation of proximal tubular sodium reabsorption by ile5 angiotensin II in the rat kidney. Pflugers Arch 1979; 381: 83-85. (Pubitemid 10241179)
71. Houillier P, Chambrey R, Achard JM, Froissart M, Poggioli J, Paillard M. Signaling pathways in the biphasic effect of angiotensin II on apical Na/H antiport activity in proximal tubule. Kidney Int 1996; 50: 1496-1505. (Pubitemid 26364254)
72. Ploth DW, Navar LG. Intrarenal effects of the renin-angiotensin system. Fed Proc 1979; 38: 2280-2285. (Pubitemid 9252334)
73. Reilly AM, Harris PJ, Williams DA. Biphasic effect of angiotensin II on intracellular sodium concentration in rat proximal tubules. Am J Physiol 1995; 269: F374-F380.
74. Burns KD, Li N. The role of angiotensin II-stimulated renal tubular transport in hypertension. Curr Hypertens Rep 2003; 5: 165-171. (Pubitemid 38898947)
75. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744-777.
76. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377: 748-750.
77. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155-163. (Pubitemid 30054167)
78. Goto M, Mukoyama M, Sugawara A, Suganami T, Kasahara M, Yahata K, Makino H, Suga S, Tanaka I, Nakao K. Expression and role of angiotensin II type 2 receptor in the kidney and mesangial cells of spontaneously hypertensive rats. Hypertens Res 2002; 25: 125-133. (Pubitemid 34196305)
79. Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 2008; 19: 84-87. (Pubitemid 351442917)
80. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 2007; 49: 341-346. (Pubitemid 46143011)
81. Siragy HM, Carey RM. The subtype 2 angiotensin receptor regulates renal prostaglandin F-2 alpha formation in conscious rats. Am J Physiol 1997; 42: R1103-R1107.
82. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999; 96: 6506-6510. (Pubitemid 29256696)
83. Siragy HM, Senbonmatsu T, Ichiki T, Inagami T, Carey RM. Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor. J Clin Invest 1999; 104: 181-188.
84. Tanaka M, Tsuchida S, Imai T, Fujii N, Miyazaki H, Ichiki T, Naruse M, Inagami T. Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice. Biochem Biophys Res Commun 1999; 258: 194-198. (Pubitemid 29287026)
85. Inagami T, Eguchi S, Numaguchi K, Motley ED, Tang H, Matsumoto T, Yamakawa T. Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. J Am Soc Nephrol 1999; 10: S57-S61. (Pubitemid 29038165)
86. Carey RM, Howell NL, Jin XH, Siragy HM. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension 2001; 38: 1272-1277. (Pubitemid 34033401)
87. Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol 2004; 142: 821-830. (Pubitemid 38998096)
88. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47: 5995-6008. (Pubitemid 39507341)
89. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 2010; 159: 709-716.
90. Haithcock D, Jiao H, Cui XL, Hopfer U, Douglas JG. Renal proximal tubular AT2 receptor: signaling and transport. J Am Soc Nephrol 1999; 10: S69-S74. (Pubitemid 29038167)
91. Gross V, Schunck WH, Honeck H, Milia AF, Kargel E, Walther T, Bader M, Inagami T, Schneider W, Luft FC. Inhibition of pressure natriuresis in mice lacking the AT2 receptor. Kidney Int 2000; 57: 191-202. (Pubitemid 30227766)
92. Padia SH, Howell NL, Siragy HM, Carey RM. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 2006; 47: 537-544. (Pubitemid 43843872)
93. Rajapakse NW, Oliver JJ, Evans RG. Nitric oxide in responses of regional kidney blood flow to vasoactive agents in anesthetized rabbits. J Cardiovasc Pharmacol 2002; 40: 210-219. (Pubitemid 34793158)
94. Bergstrom G, Evans RG. Mechanisms underlying the antihypertensive functions of the renal medulla. Acta Physiol Scand 2004; 181: 475-486. (Pubitemid 39078845)
95. Sarkis A, Liu KL, Lo M, Benzoni D. Angiotensin II and renal medullary blood flow in Lyon rats. Am J Physiol Renal Physiol 2003; 284: F365-F372. (Pubitemid 36114699)
96. Liu KL. Regulation of renal medullary circulation by the renin-angiotensin system in genetically hypertensive rats. Clin Exp Pharmacol Physiol 2009; 36: 455-461.
97. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001; 12: 157-162. (Pubitemid 33713556)
98. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA 1996; 93: 11968-11973. (Pubitemid 26347232)
99. Le MT, Vanderheyden PM, Szaszak M, Hunyady L, Vauquelin G. Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N-and C-terminal residues of angiotensin II during AT 1 receptor activation. J Biol Chem 2002; 277: 23107-23110. (Pubitemid 34952133)
100. Cesari M, Rossi GP, Pessina AC. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J Hypertens 2002; 20: 793-799. (Pubitemid 34913648)
101. Nobes MS, Harris PJ, Yamada H, Mendelsohn FAO. Effects of angiotensin on renal cortical and papillary blood flows measured by Laser-Doppler flowmetry. Am J Physiol 1991; 261: F998-F1006.
102. Gammelgaard I, Wamberg S, Bie P. Systemic effects of angiotensin III in conscious dogs during acute double blockade of the renin-angiotensin- aldosterone-system. Acta Physiol (Oxf) 2006; 188: 129-138. (Pubitemid 44337810)
103. Mustafa MR, Dharmani M, Kunheen NK, Sim MK. Effects of des-aspartateangiotensin I on the actions of angiotensin III in the renal and mesenteric vasculature of normo-and hypertensive rats. Regul Pept 2004; 120: 15-22. (Pubitemid 38726187)
104. Healy DP, Song L. Kidney aminopeptidase A and hypertension, part I: spontaneously hypertensive rats. Hypertension 1999; 33: 740-745. (Pubitemid 29091658)
105. Padia SH, Kemp BA, Howell NL, Siragy HM, Fournie-Zaluski MC, Roques BP, Carey RM. Intrarenal aminopeptidase N inhibition augments natriuretic responses to angiotensin III in angiotensin type 1 receptor-blocked rats. Hypertension 2007; 49: 625-630.
106. Harris PJ, Munro JO. Reversal by angiotensins II and III of the effects of converting enzyme inhibition on renal electrolyte excretion in rats. J Physiol 1984; 351: 491-500. (Pubitemid 14060816)
107. Britton SL, Fiksen-Olsen MJ, Houck PC, Romero JC. Intrarenal vascular effects of angiotensin II and angiotensin III in the dog. Hypertension 1983; 1: 95-101. (Pubitemid 14188073)
108. Freeman RH, Davis JO, Khosla MC. Renal and adrenal responses to [des.Asp[1]1] angiotensin I in the dog. Am J Physiol Renal Fluid Electrolyte Physiol 1987; 234: F130-F134.
109. Wamberg CH, Plovsing RR, Sandgaard NCF, Bie P. Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. Am J Physiol Regul Integr Comp Physiol 2003; 285: R971-R980. (Pubitemid 37296347)
110. Ardaillou R, Chansel D. Synthesis and effects of active fragments of angiotensin II. Kidney Int 1997; 52: 1458-1468. (Pubitemid 28032049)
111. Chansel D, Czekalski S, Vandermeersch S, Ruffet E, Fournie-Zaluski MC, Ardaillou R. Characterization of angiotensin IV-degrading enzymes and receptors on rat mesangial cells. Am J Physiol 1998; 275: F535-F542.
112. Chansel D, Vandermeersch S, Oko A, Curat C, Ardaillou R. Effects of angiotensin IV and angiotensin-(1-7) on basal and angiotensin II-stimulated cytosolic Ca2+ in mesangial cells. Eur J Pharmacol 2001; 414: 165-175. (Pubitemid 32181883)
113. Chen JK, Zimpelmann J, Harris RC, Burns KD. Angiotensin IV induces tyrosine phosphorylation of focal adhesion kinase and paxillin in proximal tubule cells. Am J Physiol-Renal Physiol 2001; 280: F980-F988.
114. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci USA 1999; 96: 13415-13420.
115. Handa RK, Harding JW, Simasko SM. Characterization and function of the bovine kidney epithelial angiotensin receptor subtype 4 using angiotensin IV and divalinal angiotensin IV as receptor ligands. J Pharmacol Exp Ther 1999; 291: 1242-1249.
116. Swanson GN, Hanesworth JM, Sardinia MF, Coleman JKM, Wright JW, Hall KL, Millerwing AV, Stobb JW, Cook VI, Harding EC, Harding JW. Discovery of a distinct binding-site for angiotensin-II (3-8), a putative angiotensin-IV receptor. Regul Pept 1992; 40: 409-419.
117. Zhang JH, Hanesworth JM, Sardinia MF, Alt JA, Wright JW, Harding JW. Structural analysis of angiotensin IV receptor (AT4) from selected bovine tissues. J Pharmacol Exp Ther 1999; 289: 1075-1783.
118. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001; 276: 48623-48626.
119. Dulin N, Madhun ZT, Chang CH, Berti-Mattera L, Dickens D, Douglas JG. Angiotensin IV receptors and signaling in opossum kidney cells. Am J Physiol 1995; 269: F644-F652. (Pubitemid 3006014)
120. Garreau I, Chansel D, Vandermeersch S, Fruitier I, Piot JM, Ardaillou R. Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Peptides 1998; 19: 1339-1348. (Pubitemid 28514438)
121. Czekalski S, Chansel D, Vandermeersch S, Ronco P, Ardaillou R. Evidence for angiotensin IV receptors in human collecting duct cells. Kidney Int 1996; 50: 1125-1131. (Pubitemid 26342801)
122. Handa RK. Characterization and signaling of the AT(4) receptor in human proximal tubule epithelial (HK-2) cells. J Am Soc Nephrol 2001; 12: 440-449. (Pubitemid 32180012)
123. Millerwing AV, Hanesworth JM, Sardinia MF, Hall KL, Wright JW, Speth RC, Grove KL, Harding JW. Central angiotensin-IV binding-sites-distribution and specificity in Guinea-Pig brain. J Pharmacol Exp Ther 1993; 266: 1718-1726. (Pubitemid 24175827)
124. Chai SY, Bastias MA, Clune EF, Matsacos DJ, Mustafa T, Lee JH, McDowall SG, Paxinos G, Mendelsohn FA, Albiston AL. Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography. J Chem Neuroanat 2000; 20: 339-348. (Pubitemid 32162891)
125. Dupont AG, Yang R, Smolders I, Vanderheyden P. IRAP and AT(1) receptor mediated effects of angiotensin IV. J Intern Med 2009; 265: 401-403.
126. Hamilton TA, Handa RK, Harding JW, Wright JW. A role for the angiotensin IV/AT(4) system in mediating natriuresis in the rat. Peptides 2001; 22: 935-944. (Pubitemid 32522971)
127. Patel JM, Martens JR, Li YD, Gelband CH, Raizada MK, Block ER. Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. Am J Physiol 1998; 275: L1061-L1068.
128. Patel JM, Li YD, Zhang J, Gelband CH, Raizada MK, Block ER. Increased expression of calreticulin is linked to ANG IV-mediated activation of lung endothelial NOS. Am J Physiol 1999; 277: L794-L801. (Pubitemid 29522646)
129. Kramar EA, Krishnan R, Harding JW, Wright JW. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul Pept 1998; 74: 185-192. (Pubitemid 28288981)
130. Yoshida M, Kikukawa M, Hisa H, Satoh S. Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3-8). Br J Pharmacol 1996; 117: 885-890. (Pubitemid 26075965)
131. Gardiner SM, Kemp PA, March JE, Bennett T. Regional haemodynamic effects of angiotensin II (3-8) in conscious rats. Br J Pharmacol 1993; 110: 159-162. (Pubitemid 23257773)
132. Fitzgerald SM, Evans RG, Bergstrom G, Anderson WP. Renal hemodynamic responses to intrarenal infusion of ligands for the putative angiotensin IV receptor in anesthetized rats. J Cardiovasc Pharmacol 1999; 34: 206-211. (Pubitemid 29350501)
133. Demaegdt H, Vanderheyden P, De Backer JP, Mosselmans S, Laeremans H, Le MT, Kersemans V, Michotte Y, Vauquelin G. Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity. Biochem Pharmacol 2004; 68: 885-892. (Pubitemid 39044516)
134. Dworkin LD, Brenner BM. The renal circulation. In Brenner BM, Rector FC Jr (eds). The Kidney. WB Saunder: Philadelphia, PA, 1991, p 164.
135. Van Rodijnen WF, Van Lambalgen TA, Van Wijhe MH, Tangelder GJ, Ter Wee PM. Renal microvascular actions of angiotensin II fragments. Am J Physiol Renal Physiol 2002; 283: F86-F92. (Pubitemid 34680475)
136. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
137. Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin(1-7) by angiotensin converting enzyme. Hypertension 1998; 31: 362-367.
138. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de BI, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263. (Pubitemid 36842532)
139. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005; 45: 960-966. (Pubitemid 40628944)
140. Santos RA, Simoes e Silva AC, Magaldi AJ, Khosla MC, Cesar KR, Passaglio KT, Baracho NC. Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension 1996; 27: 875-884. (Pubitemid 26113834)
141. Sampaio WO, Nascimento AAS, Santos RAS. Regulation of cardiovascular signaling by kinins and products of similar converting enzyme systems-systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 2003; 284: H1985-H1994.
142. Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 1998; 11: 137-146. (Pubitemid 28137604)
143. Dharmani M, Mustafa MR, Achike FI, Sim MK. Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 561: 144-150. (Pubitemid 46435855)
144. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides 1993; 14: 883-891.
145. Van Der Wouden EA, Ochodnicky P, Van Dokkum RPE, Roks AJM, Deelman LE, de Zeeuw D, Henning RH. The role of angiotensin(1-7) in renal vasculature of the rat. J Hypertens 2006; 24: 1971-1978. (Pubitemid 44371263)
146. Handa RK, Ferrario CM, Strandhoy JW. Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am J Physiol 1996; 270: F141-F147.
147. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23: 439-449. (Pubitemid 24102039)
148. SimoeseSilva AC, Baracho NCV, Passaglio KT, Santos RAS. Renal actions of angiotensin-( 1-7). Braz J Med Biol Res 1997; 30: 503-513.
149. Ren YL, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 2002; 39: 799-802. (Pubitemid 34252879)
150. Heller J, Kramer HJ, Maly J, Cervenka L, Horacek V. Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney Blood Press Res 2000; 23: 89-94. (Pubitemid 30175627)
151. Kono T, Taniguchi A, Imura H, Oseko F, Khosla MC. Biological activities of angiotensin II(1-6) hexapeptide and angiotensin II(1-7) heptapeptide in man. Life Sci 1986; 38: 1515-1519. (Pubitemid 16069406)
152. Davie AP, McMurray JJ. Effect of angiotensin(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 1999; 34: 457-460. (Pubitemid 29426763)
153. Yang R, Gembardt F, Walther T, Lukaszuk A, Tourwe D, Vanderheyden P, Smolders I, Dupont AG. Pressor and renal effects of angiotensin A [abstract]. J Hypertens 2009; 27: S453.
154. Badejo Jr A, Greco AJ, Casey DB, Cook JL, Murthy SN, Kadowitz PJ. Analysis of hemodynamic responses and the proliferative effect of the novel angiotensin peptide Angiotensin A. Abstract. http://www.fasebj.org/cgi/content/ meeting-abstract/23/1-MeetingAbstracts/935.2; data accessed 4 March 2011.
155. Capponi AM, Catt KJ. Angiotensin II receptors in adrenal cortex and uterus. Binding and activation properties of angiotensin analogues. J Biol Chem 1979; 254: 5120-5127. (Pubitemid 9227466)
156. Lanckmans K, Stragier B, Sarre S, Smolders I, Michotte Y. Nano-LC-MS/MS for the monitoring of angiotensin IV in rat brain microdialysates: limitations and possibilities. J Sep Sci 2007; 30: 2217-2224. (Pubitemid 47497022)
157. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
158. Unger T, Dahlö f B. Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential. J Renin 2010; 11: 75-77.
159. Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin 2010; 11: 19-31.